Table 2.

Follow‐up data

Patient ID	Disease months Visit 1/2	mRS Visit 1/2	Antibody titer		PAS (% change) Visit 1/2	Change of medication Visit 1 → 2
			Serum Visit 1/2	CSF Visit 1/2
4	14/38	3/2	32/100	1/n.d.	−57.63/−13.95 (↑)	No
7	42/66	2/1	0/0	0/0	−6.47/+1.89 (↑)	LEV → Escitalopram
10	46/61	1/1	32/0	1/0	−8.25/−1.56 (↑)	No
15	57/74	1/0	10/32	32/n.d.	−58.71/+101.28 (↑)	No
17	5/13	2/1	100/100	10/n.d.	−39.61/−18.49 (↑)	VAL → LTG
21	8/12	3/3	320/100	32/32	−35.01/−43.88 (↓)	Quetiapin → No

mRS, modified Rankin Scale; CSF, cerebrospinal fluid; PAS, paired associative stimulation; n.d., not determined; LTG, lamotrigin; VPA, valproate; LEV, levetiracetam.